The role of interleukin-24 in atopic dermatitis
Atopic dermatitis (AD) is characterized by skin barrier disruption, type 2 immune dysregulation, chronic pruritus, and abnormal colonization by Staphylococcus aureus (S. aureus). Tapinarof, an aryl hydrocarbon receptor modulator, has been demonstrated to attenuate the development of AD in clinical s...
Saved in:
Main Authors: | Yen Hai Vu, Masutaka Furue, Gaku Tsuji |
---|---|
Format: | article |
Language: | EN |
Published: |
Open Exploration Publishing Inc.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/856e2ee9c914464eabc7d770cfa8b188 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
by: Miguel Nogueira, et al.
Published: (2021) -
The New Era of Biologics in Atopic Dermatitis: A Review
by: Simon Schneider, et al.
Published: (2021) -
Dupilumab side effect in a patient with atopic dermatitis: a case report study
by: Albader SS, et al.
Published: (2019) -
Interleukin-22 and keratinocytes; pathogenic implications in skin inflammation
by: Masutaka Furue, et al.
Published: (2021) -
Efficacy of Dupilumab for Atopic Dermatitis According to Clinical Course and Clinical Findings: A Multicentre Retrospective Study
by: Takeshi Nakahara, et al.
Published: (2021)